ID   CDK6_HUMAN              Reviewed;         326 AA.
AC   Q00534; A4D1G0;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   12-OCT-2022, entry version 228.
DE   RecName: Full=Cyclin-dependent kinase 6;
DE            EC=2.7.11.22;
DE   AltName: Full=Cell division protein kinase 6;
DE   AltName: Full=Serine/threonine-protein kinase PLSTIRE;
GN   Name=CDK6; Synonyms=CDKN6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1639063; DOI=10.1002/j.1460-2075.1992.tb05360.x;
RA   Meyerson M., Enders G.H., Wu C.-L., Su L.-K., Gorka C., Nelson C.,
RA   Harlow E., Tsai L.-H.;
RT   "A family of human cdc2-related protein kinases.";
RL   EMBO J. 11:2909-2917(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION AS PRB/RB1 KINASE, TISSUE SPECIFICITY, AND INTERACTION WITH D-TYPE
RP   CYCLINS.
RX   PubMed=8114739; DOI=10.1128/mcb.14.3.2077-2086.1994;
RA   Meyerson M., Harlow E.;
RT   "Identification of G1 kinase activity for cdk6, a novel cyclin D partner.";
RL   Mol. Cell. Biol. 14:2077-2086(1994).
RN   [9]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH D-TYPE CYCLINS; CDKN2D; HSP90AB1
RP   AND CDC37.
RX   PubMed=9482106; DOI=10.1038/sj.onc.1201570;
RA   Mahony D., Parry D.A., Lees E.;
RT   "Active cdk6 complexes are predominantly nuclear and represent only a
RT   minority of the cdk6 in T cells.";
RL   Oncogene 16:603-611(1998).
RN   [10]
RP   FUNCTION IN DIFFERENTIATION, AND ACTIVITY REGULATION.
RX   PubMed=12833137; DOI=10.1038/sj.onc.1206484;
RA   Matushansky I., Radparvar F., Skoultchi A.I.;
RT   "CDK6 blocks differentiation: coupling cell proliferation to the block to
RT   differentiation in leukemic cells.";
RL   Oncogene 22:4143-4149(2003).
RN   [11]
RP   FUNCTION IN CELL PROLIFERATION.
RX   PubMed=14985467;
RA   Lucas J.J., Domenico J., Gelfand E.W.;
RT   "Cyclin-dependent kinase 6 inhibits proliferation of human mammary
RT   epithelial cells.";
RL   Mol. Cancer Res. 2:105-114(2004).
RN   [12]
RP   FUNCTION IN DIFFERENTIATION.
RX   PubMed=15254224; DOI=10.1128/mcb.24.15.6560-6568.2004;
RA   Ogasawara T., Kawaguchi H., Jinno S., Hoshi K., Itaka K., Takato T.,
RA   Nakamura K., Okayama H.;
RT   "Bone morphogenetic protein 2-induced osteoblast differentiation requires
RT   Smad-mediated down-regulation of Cdk6.";
RL   Mol. Cell. Biol. 24:6560-6568(2004).
RN   [13]
RP   INTERACTION WITH FBXO7, AND SUBCELLULAR LOCATION.
RX   PubMed=16096642; DOI=10.1038/sj.emboj.7600775;
RA   Laman H., Funes J.M., Ye H., Henderson S., Galinanes-Garcia L., Hara E.,
RA   Knowles P., McDonald N., Boshoff C.;
RT   "Transforming activity of Fbxo7 is mediated specifically through regulation
RT   of cyclin D/cdk6.";
RL   EMBO J. 24:3104-3116(2005).
RN   [14]
RP   FUNCTION AS PRB/RB1 KINASE.
RX   PubMed=15809340; DOI=10.1093/jb/mvi050;
RA   Takaki T., Fukasawa K., Suzuki-Takahashi I., Semba K., Kitagawa M.,
RA   Taya Y., Hirai H.;
RT   "Preferences for phosphorylation sites in the retinoblastoma protein of D-
RT   type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro.";
RL   J. Biochem. 137:381-386(2005).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-13 AND TYR-24, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [16]
RP   INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal
RT   differential cellular gene expression in response to enterovirus 71
RT   infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [17]
RP   FUNCTION IN MYELOID DIFFERENTIATION, AND INTERACTION WITH RUNX1.
RX   PubMed=17431401; DOI=10.1038/sj.emboj.7601675;
RA   Fujimoto T., Anderson K., Jacobsen S.E., Nishikawa S.I., Nerlov C.;
RT   "Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding
RT   and Runx1-C/EBPalpha interaction.";
RL   EMBO J. 26:2361-2370(2007).
RN   [18]
RP   FUNCTION IN SENESCENCE.
RX   PubMed=17420273; DOI=10.1128/mcb.02286-06;
RA   Ruas M., Gregory F., Jones R., Poolman R., Starborg M., Rowe J.,
RA   Brookes S., Peters G.;
RT   "CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-
RT   independent mechanisms.";
RL   Mol. Cell. Biol. 27:4273-4282(2007).
RN   [19]
RP   INDUCTION BY NANOG.
RX   PubMed=19139263; DOI=10.1083/jcb.200801009;
RA   Zhang X., Neganova I., Przyborski S., Yang C., Cooke M., Atkinson S.P.,
RA   Anyfantis G., Fenyk S., Keith W.N., Hoare S.F., Hughes O., Strachan T.,
RA   Stojkovic M., Hinds P.W., Armstrong L., Lako M.;
RT   "A role for NANOG in G1 to S transition in human embryonic stem cells
RT   through direct binding of CDK6 and CDC25A.";
RL   J. Cell Biol. 184:67-82(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-24; THR-49; THR-70 AND
RP   THR-325, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-264, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [23]
RP   FUNCTION IN BETA-CELL PROLIFERATION, TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20668294; DOI=10.2337/db09-1776;
RA   Fiaschi-Taesch N.M., Salim F., Kleinberger J., Troxell R.,
RA   Cozar-Castellano I., Selk K., Cherok E., Takane K.K., Scott D.K.,
RA   Stewart A.F.;
RT   "Induction of human beta-cell proliferation and engraftment using a single
RT   G1/S regulatory molecule, cdk6.";
RL   Diabetes 59:1926-1936(2010).
RN   [24]
RP   FUNCTION AS NPM1 KINASE, AND INTERACTION WITH KSHV V-CYCLIN.
RX   PubMed=20333249; DOI=10.1371/journal.ppat.1000818;
RA   Sarek G., Jaerviluoma A., Moore H.M., Tojkander S., Vartia S.,
RA   Biberfeld P., Laiho M., Ojala P.M.;
RT   "Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.";
RL   PLoS Pathog. 6:E1000818-E1000818(2010).
RN   [25]
RP   REVIEW ON CELL DIFFERENTIATION.
RX   PubMed=16294322; DOI=10.1002/jcb.20712;
RA   Grossel M.J., Hinds P.W.;
RT   "Beyond the cell cycle: a new role for Cdk6 in differentiation.";
RL   J. Cell. Biochem. 97:485-493(2006).
RN   [26]
RP   REVIEW ON CELL CYCLE CONTROL, INHIBITORS, AND GENE FAMILY.
RX   PubMed=19238148; DOI=10.1038/nrc2602;
RA   Malumbres M., Barbacid M.;
RT   "Cell cycle, CDKs and cancer: a changing paradigm.";
RL   Nat. Rev. Cancer 9:153-166(2009).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [29]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN MCPH12, AND VARIANT MCPH12
RP   THR-197.
RX   PubMed=23918663; DOI=10.1093/hmg/ddt374;
RA   Hussain M.S., Baig S.M., Neumann S., Peche V.S., Szczepanski S.,
RA   Nurnberg G., Tariq M., Jameel M., Khan T.N., Fatima A., Malik N.A.,
RA   Ahmad I., Altmuller J., Frommolt P., Thiele H., Hohne W., Yigit G.,
RA   Wollnik B., Neubauer B.A., Nurnberg P., Noegel A.A.;
RT   "CDK6 associates with the centrosome during mitosis and is mutated in a
RT   large Pakistani family with primary microcephaly.";
RL   Hum. Mol. Genet. 22:5199-5214(2013).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF COMPLEXES WITH INK4A AND INK4D.
RX   PubMed=9751050; DOI=10.1038/26155;
RA   Russo A.A., Tong L., Lee J.O., Jeffrey P.D., Pavletich N.P.;
RT   "Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the
RT   tumour suppressor p16INK4a.";
RL   Nature 395:237-243(1998).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) IN COMPLEX WITH INHIBITOR
RP   CDKN2C/P18-INK4C.
RX   PubMed=11124804; DOI=10.1101/gad.851100;
RA   Jeffrey P.D., Tong L., Pavletich N.P.;
RT   "Structural basis of inhibition of CDK-cyclin complexes by INK4
RT   inhibitors.";
RL   Genes Dev. 14:3115-3125(2000).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 1-308 IN COMPLEX WITH HERPESVIRUS
RP   SAIMIRI V-CYCLIN/ECLF2, AND PHOSPHORYLATION AT THR-177.
RX   PubMed=11828325; DOI=10.1038/nsb756;
RA   Schulze-Gahmen U., Kim S.-H.;
RT   "Structural basis for CDK6 activation by a virus-encoded cyclin.";
RL   Nat. Struct. Biol. 9:177-181(2002).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 1-308 IN COMPLEX WITH INHIBITOR.
RX   PubMed=15689157; DOI=10.1021/jm049353p;
RA   Lu H., Chang D.J., Baratte B., Meijer L., Schulze-Gahmen U.;
RT   "Crystal structure of a human cyclin-dependent kinase 6 complex with a
RT   flavonol inhibitor, fisetin.";
RL   J. Med. Chem. 48:737-743(2005).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 1-308 IN COMPLEX WITH INHIBITORS
RP   AND V-CYCLIN.
RX   PubMed=16789739; DOI=10.1021/jm0600388;
RA   Lu H., Schulze-Gahmen U.;
RT   "Toward understanding the structural basis of cyclin-dependent kinase 6
RT   specific inhibition.";
RL   J. Med. Chem. 49:3826-3831(2006).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 1-301 IN COMPLEX WITH INHIBITORS.
RX   PubMed=21038853; DOI=10.1021/jm100571n;
RA   Cho Y.S., Borland M., Brain C., Chen C.H.-T., Cheng H., Chopra R.,
RA   Chung K., Groarke J., He G., Hou Y., Kim S., Kovats S., Lu Y., O'Reilly M.,
RA   Shen J., Smith T., Trakshel G., Voegtle M., Xu M., Xu M., Sung M.J.;
RT   "4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent
RT   kinase 4/6.";
RL   J. Med. Chem. 53:7938-7957(2010).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-110 AND LEU-199.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in the control of
CC       the cell cycle and differentiation; promotes G1/S transition.
CC       Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins
CC       during interphase at G1 to form a pRB/RB1 kinase and controls the
CC       entrance into the cell cycle. Involved in initiation and maintenance of
CC       cell cycle exit during cell differentiation; prevents cell
CC       proliferation and regulates negatively cell differentiation, but is
CC       required for the proliferation of specific cell types (e.g. erythroid
CC       and hematopoietic cells). Essential for cell proliferation within the
CC       dentate gyrus of the hippocampus and the subventricular zone of the
CC       lateral ventricles. Required during thymocyte development. Promotes the
CC       production of newborn neurons, probably by modulating G1 length.
CC       Promotes, at least in astrocytes, changes in patterns of gene
CC       expression, changes in the actin cytoskeleton including loss of stress
CC       fibers, and enhanced motility during cell differentiation. Prevents
CC       myeloid differentiation by interfering with RUNX1 and reducing its
CC       transcription transactivation activity, but promotes proliferation of
CC       normal myeloid progenitors. Delays senescence. Promotes the
CC       proliferation of beta-cells in pancreatic islets of Langerhans. May
CC       play a role in the centrosome organization during the cell cycle phases
CC       (PubMed:23918663). {ECO:0000269|PubMed:12833137,
CC       ECO:0000269|PubMed:14985467, ECO:0000269|PubMed:15254224,
CC       ECO:0000269|PubMed:15809340, ECO:0000269|PubMed:17420273,
CC       ECO:0000269|PubMed:17431401, ECO:0000269|PubMed:20333249,
CC       ECO:0000269|PubMed:20668294, ECO:0000269|PubMed:23918663,
CC       ECO:0000269|PubMed:8114739}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.22;
CC   -!- ACTIVITY REGULATION: Inhibited by INK4 proteins (CDKN2C/p18-INK4c),
CC       aminopurvalanol, PD0332991, 4-(Pyrazol-4-yl)-pyrimidines and fisetin, a
CC       flavonol inhibitor. Activated by Thr-177 phosphorylation and Tyr-24
CC       dephosphorylation (By similarity). Stimulated by cyclin from
CC       herpesvirus saimiri (V-cyclin/ECLF2). Rapidly down-regulated prior to
CC       cell differentiation (e.g. erythroid and osteoblast). {ECO:0000250,
CC       ECO:0000269|PubMed:12833137}.
CC   -!- SUBUNIT: Interaction with D-type G1 cyclins. Cyclin binding promotes
CC       enzyme activation by phosphorylation at Thr-177 (By similarity). Binds
CC       to RUNX1, CDKN2D, FBXO7 and CDKN2C/p18-INK4c. Forms a cytoplasmic
CC       complex with Hsp90/HSP90AB1 and CDC37. FBXO7-binding promotes D-type
CC       cyclin binding. Interacts with Kaposi's sarcoma herpesvirus (KSHV) V-
CC       cyclin and herpesvirus saimiri (V-cyclin/ECLF2); the CDK6/V-cyclin
CC       complex phosphorylates NPM1 and thus lead to viral reactivation by
CC       reducing viral LANA levels. {ECO:0000250, ECO:0000269|PubMed:11124804,
CC       ECO:0000269|PubMed:11828325, ECO:0000269|PubMed:15689157,
CC       ECO:0000269|PubMed:16096642, ECO:0000269|PubMed:16789739,
CC       ECO:0000269|PubMed:17431401, ECO:0000269|PubMed:20333249,
CC       ECO:0000269|PubMed:21038853, ECO:0000269|PubMed:8114739,
CC       ECO:0000269|PubMed:9482106}.
CC   -!- INTERACTION:
CC       Q00534; P41238: APOBEC1; NbExp=3; IntAct=EBI-295663, EBI-12819523;
CC       Q00534; P24385: CCND1; NbExp=4; IntAct=EBI-295663, EBI-375001;
CC       Q00534; P30281: CCND3; NbExp=30; IntAct=EBI-295663, EBI-375013;
CC       Q00534; P51946: CCNH; NbExp=5; IntAct=EBI-295663, EBI-741406;
CC       Q00534; Q14094: CCNI; NbExp=3; IntAct=EBI-295663, EBI-1104653;
CC       Q00534; Q16543: CDC37; NbExp=3; IntAct=EBI-295663, EBI-295634;
CC       Q00534; P38936: CDKN1A; NbExp=2; IntAct=EBI-295663, EBI-375077;
CC       Q00534; P42771: CDKN2A; NbExp=16; IntAct=EBI-295663, EBI-375053;
CC       Q00534; P42772: CDKN2B; NbExp=16; IntAct=EBI-295663, EBI-711280;
CC       Q00534; P42773: CDKN2C; NbExp=25; IntAct=EBI-295663, EBI-711290;
CC       Q00534; P55273: CDKN2D; NbExp=22; IntAct=EBI-295663, EBI-745859;
CC       Q00534; Q08050-1: FOXM1; NbExp=2; IntAct=EBI-295663, EBI-866499;
CC       Q00534; P08238: HSP90AB1; NbExp=2; IntAct=EBI-295663, EBI-352572;
CC       Q00534; Q5XKR4: OTP; NbExp=3; IntAct=EBI-295663, EBI-12865884;
CC       Q00534; Q01196: RUNX1; NbExp=5; IntAct=EBI-295663, EBI-925904;
CC       Q00534; Q9C019: TRIM15; NbExp=3; IntAct=EBI-295663, EBI-2342111;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell projection, ruffle.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
CC       {ECO:0000269|PubMed:23918663}. Note=Localized to the ruffling edge of
CC       spreading fibroblasts. Kinase activity only in nucleus. Localized to
CC       the cytosol of neurons and showed prominent staining around either side
CC       of the nucleus (By similarity). Present in the cytosol and in the
CC       nucleus in interphase cells and at the centrosome during mitosis from
CC       prophase to telophase (PubMed:23918663). {ECO:0000250|UniProtKB:Q64261,
CC       ECO:0000269|PubMed:23918663}.
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously. Accumulates in squamous
CC       cell carcinomas, proliferating hematopoietic progenitor cells, beta-
CC       cells of pancreatic islets of Langerhans, and neuroblastomas. Reduced
CC       levels in differentiating cells. {ECO:0000269|PubMed:20668294,
CC       ECO:0000269|PubMed:8114739}.
CC   -!- INDUCTION: Down-regulated in response to enterovirus 71 (EV71)
CC       infection. Induced by NANOG during S-phase entry.
CC       {ECO:0000269|PubMed:16548883, ECO:0000269|PubMed:19139263}.
CC   -!- PTM: Thr-177 phosphorylation and Tyr-24 dephosphorylation promotes
CC       kinase activity. {ECO:0000269|PubMed:11828325}.
CC   -!- POLYMORPHISM: Genetic variations in CDK6 may influence stature as a
CC       quantitative trait, contributing to the stature quantitative trait
CC       locus 11 (STQTL11) [MIM:612223]. Adult height is an easily observable
CC       and highly heritable complex continuous trait. Because of this, it is a
CC       model trait for studying genetic influence on quantitative traits.
CC   -!- DISEASE: Microcephaly 12, primary, autosomal recessive (MCPH12)
CC       [MIM:616080]: A form of microcephaly, a disease defined as a head
CC       circumference more than 3 standard deviations below the age-related
CC       mean. Brain weight is markedly reduced and the cerebral cortex is
CC       disproportionately small. {ECO:0000269|PubMed:23918663}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Over-expressed in some leukemias and malignancies
CC       (including sarcoma, glioma, breast tumors, lymphoma and melanoma) as a
CC       consequence of nearby translocations.
CC   -!- MISCELLANEOUS: Enhances beta-cells engraftment in pancreatic islets of
CC       Langerhans of diabetic patients.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdk6/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X66365; CAA47008.1; -; mRNA.
DR   EMBL; AY128534; AAM76970.1; -; Genomic_DNA.
DR   EMBL; AK313491; BAG36273.1; -; mRNA.
DR   EMBL; AC000065; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC004128; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC004011; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236949; EAL24146.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76827.1; -; Genomic_DNA.
DR   EMBL; BC052264; AAH52264.1; -; mRNA.
DR   CCDS; CCDS5628.1; -.
DR   PIR; S23387; S23387.
DR   RefSeq; NP_001138778.1; NM_001145306.1.
DR   RefSeq; NP_001250.1; NM_001259.6.
DR   RefSeq; XP_006715898.1; XM_006715835.2.
DR   PDB; 1BI7; X-ray; 3.40 A; A=1-326.
DR   PDB; 1BI8; X-ray; 2.80 A; A/C=1-326.
DR   PDB; 1BLX; X-ray; 1.90 A; A=1-326.
DR   PDB; 1G3N; X-ray; 2.90 A; A/E=1-326.
DR   PDB; 1JOW; X-ray; 3.10 A; B=1-308.
DR   PDB; 1XO2; X-ray; 2.90 A; B=1-308.
DR   PDB; 2EUF; X-ray; 3.00 A; B=1-308.
DR   PDB; 2F2C; X-ray; 2.80 A; B=1-308.
DR   PDB; 3NUP; X-ray; 2.60 A; A=1-301.
DR   PDB; 3NUX; X-ray; 2.70 A; A=1-301.
DR   PDB; 4AUA; X-ray; 2.31 A; A=1-301.
DR   PDB; 4EZ5; X-ray; 2.70 A; A=1-301.
DR   PDB; 4TTH; X-ray; 2.90 A; B=1-326.
DR   PDB; 5L2I; X-ray; 2.75 A; A=1-301.
DR   PDB; 5L2S; X-ray; 2.27 A; A=1-301.
DR   PDB; 5L2T; X-ray; 2.37 A; A=1-301.
DR   PDB; 6OQL; X-ray; 2.71 A; A=11-301.
DR   PDB; 6OQO; X-ray; 1.98 A; A=11-301.
DR   PDBsum; 1BI7; -.
DR   PDBsum; 1BI8; -.
DR   PDBsum; 1BLX; -.
DR   PDBsum; 1G3N; -.
DR   PDBsum; 1JOW; -.
DR   PDBsum; 1XO2; -.
DR   PDBsum; 2EUF; -.
DR   PDBsum; 2F2C; -.
DR   PDBsum; 3NUP; -.
DR   PDBsum; 3NUX; -.
DR   PDBsum; 4AUA; -.
DR   PDBsum; 4EZ5; -.
DR   PDBsum; 4TTH; -.
DR   PDBsum; 5L2I; -.
DR   PDBsum; 5L2S; -.
DR   PDBsum; 5L2T; -.
DR   PDBsum; 6OQL; -.
DR   PDBsum; 6OQO; -.
DR   AlphaFoldDB; Q00534; -.
DR   SMR; Q00534; -.
DR   BioGRID; 107456; 198.
DR   ComplexPortal; CPX-2013; Cyclin D3-CDK6 complex.
DR   ComplexPortal; CPX-2014; Cyclin D1-CDK6 complex.
DR   CORUM; Q00534; -.
DR   DIP; DIP-687N; -.
DR   IntAct; Q00534; 117.
DR   MINT; Q00534; -.
DR   STRING; 9606.ENSP00000265734; -.
DR   BindingDB; Q00534; -.
DR   ChEMBL; CHEMBL2508; -.
DR   DrugBank; DB07379; (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol.
DR   DrugBank; DB12001; Abemaciclib.
DR   DrugBank; DB03496; Alvocidib.
DR   DrugBank; DB07795; Fisetin.
DR   DrugBank; DB09073; Palbociclib.
DR   DrugBank; DB11730; Ribociclib.
DR   DrugBank; DB15442; Trilaciclib.
DR   DrugCentral; Q00534; -.
DR   GuidetoPHARMACOLOGY; 1978; -.
DR   MoonDB; Q00534; Predicted.
DR   iPTMnet; Q00534; -.
DR   MetOSite; Q00534; -.
DR   PhosphoSitePlus; Q00534; -.
DR   BioMuta; CDK6; -.
DR   DMDM; 266423; -.
DR   EPD; Q00534; -.
DR   jPOST; Q00534; -.
DR   MassIVE; Q00534; -.
DR   MaxQB; Q00534; -.
DR   PaxDb; Q00534; -.
DR   PeptideAtlas; Q00534; -.
DR   PRIDE; Q00534; -.
DR   ProteomicsDB; 57851; -.
DR   Antibodypedia; 1130; 1002 antibodies from 42 providers.
DR   DNASU; 1021; -.
DR   Ensembl; ENST00000265734.8; ENSP00000265734.4; ENSG00000105810.10.
DR   Ensembl; ENST00000424848.3; ENSP00000397087.3; ENSG00000105810.10.
DR   GeneID; 1021; -.
DR   KEGG; hsa:1021; -.
DR   MANE-Select; ENST00000424848.3; ENSP00000397087.3; NM_001145306.2; NP_001138778.1.
DR   UCSC; uc010lez.4; human.
DR   CTD; 1021; -.
DR   DisGeNET; 1021; -.
DR   GeneCards; CDK6; -.
DR   HGNC; HGNC:1777; CDK6.
DR   HPA; ENSG00000105810; Tissue enhanced (lymphoid).
DR   MalaCards; CDK6; -.
DR   MIM; 603368; gene.
DR   MIM; 612223; phenotype.
DR   MIM; 616080; phenotype.
DR   neXtProt; NX_Q00534; -.
DR   OpenTargets; ENSG00000105810; -.
DR   Orphanet; 2512; Autosomal recessive primary microcephaly.
DR   PharmGKB; PA103; -.
DR   VEuPathDB; HostDB:ENSG00000105810; -.
DR   eggNOG; KOG0594; Eukaryota.
DR   GeneTree; ENSGT00940000157957; -.
DR   HOGENOM; CLU_000288_181_1_1; -.
DR   InParanoid; Q00534; -.
DR   OMA; QWNSGEE; -.
DR   OrthoDB; 988547at2759; -.
DR   PhylomeDB; Q00534; -.
DR   TreeFam; TF101022; -.
DR   BRENDA; 2.7.11.22; 2681.
DR   PathwayCommons; Q00534; -.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-8934593; Regulation of RUNX1 Expression and Activity.
DR   Reactome; R-HSA-9630794; Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6.
DR   Reactome; R-HSA-9632700; Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6.
DR   Reactome; R-HSA-9661069; Defective binding of RB1 mutants to E2F1,(E2F2, E2F3).
DR   Reactome; R-HSA-9754119; Drug-mediated inhibition of CDK4/CDK6 activity.
DR   SignaLink; Q00534; -.
DR   SIGNOR; Q00534; -.
DR   BioGRID-ORCS; 1021; 351 hits in 1134 CRISPR screens.
DR   ChiTaRS; CDK6; human.
DR   EvolutionaryTrace; Q00534; -.
DR   GeneWiki; Cyclin-dependent_kinase_6; -.
DR   GenomeRNAi; 1021; -.
DR   Pharos; Q00534; Tclin.
DR   PRO; PR:Q00534; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q00534; protein.
DR   Bgee; ENSG00000105810; Expressed in adrenal tissue and 182 other tissues.
DR   Genevisible; Q00534; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0097132; C:cyclin D2-CDK6 complex; IEA:Ensembl.
DR   GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016592; C:mediator complex; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0001726; C:ruffle; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IDA:BHF-UCL.
DR   GO; GO:0030332; F:cyclin binding; IPI:BHF-UCL.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0098770; F:FBXO family protein binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IBA:GO_Central.
DR   GO; GO:0014002; P:astrocyte development; ISS:UniProtKB.
DR   GO; GO:0043697; P:cell dedifferentiation; IMP:BHF-UCL.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0021542; P:dentate gyrus development; ISS:UniProtKB.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:UniProtKB.
DR   GO; GO:0048699; P:generation of neurons; ISS:UniProtKB.
DR   GO; GO:0042063; P:gliogenesis; IMP:BHF-UCL.
DR   GO; GO:0060218; P:hematopoietic stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0021670; P:lateral ventricle development; ISS:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; TAS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; TAS:UniProtKB.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IDA:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0045656; P:negative regulation of monocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0045638; P:negative regulation of myeloid cell differentiation; IDA:UniProtKB.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; IDA:BHF-UCL.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IMP:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0051726; P:regulation of cell cycle; IBA:GO_Central.
DR   GO; GO:2000145; P:regulation of cell motility; ISS:UniProtKB.
DR   GO; GO:0045646; P:regulation of erythrocyte differentiation; IMP:BHF-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0003323; P:type B pancreatic cell development; IDA:UniProtKB.
DR   CDD; cd07862; STKc_CDK6; 1.
DR   InterPro; IPR028788; CDK6.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Cell cycle; Cell division;
KW   Cell projection; Cytoplasm; Cytoskeleton; Differentiation; Disease variant;
KW   Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; Primary microcephaly;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN           1..326
FT                   /note="Cyclin-dependent kinase 6"
FT                   /id="PRO_0000085789"
FT   DOMAIN          13..300
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        145
FT                   /note="Proton acceptor"
FT   BINDING         19..27
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         43
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         13
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455"
FT   MOD_RES         24
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         49
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         70
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         177
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:11828325"
FT   MOD_RES         264
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         325
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   VARIANT         110
FT                   /note="D -> N (in dbSNP:rs35654944)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041978"
FT   VARIANT         197
FT                   /note="A -> T (in MCPH12; dbSNP:rs606231255)"
FT                   /evidence="ECO:0000269|PubMed:23918663"
FT                   /id="VAR_072638"
FT   VARIANT         199
FT                   /note="P -> L (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041979"
FT   HELIX           9..11
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          13..22
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          25..32
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   TURN            33..37
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          39..49
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   HELIX           58..70
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          79..87
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          89..99
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          102..104
FT                   /evidence="ECO:0007829|PDB:6OQO"
FT   HELIX           105..111
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   TURN            113..115
FT                   /evidence="ECO:0007829|PDB:4TTH"
FT   HELIX           119..138
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   HELIX           148..150
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          151..153
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          159..161
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   HELIX           172..176
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          180..182
FT                   /evidence="ECO:0007829|PDB:1BI8"
FT   HELIX           183..185
FT                   /evidence="ECO:0007829|PDB:2F2C"
FT   HELIX           188..191
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   HELIX           199..214
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   HELIX           224..235
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   HELIX           240..242
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          245..249
FT                   /evidence="ECO:0007829|PDB:1XO2"
FT   HELIX           251..253
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   HELIX           262..264
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   STRAND          266..268
FT                   /evidence="ECO:0007829|PDB:1XO2"
FT   HELIX           271..280
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   TURN            285..287
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   HELIX           291..295
FT                   /evidence="ECO:0007829|PDB:1BLX"
FT   HELIX           298..300
FT                   /evidence="ECO:0007829|PDB:1BLX"
SQ   SEQUENCE   326 AA;  36938 MW;  571733EE6BE7FD4A CRC64;
     MEKDGLCRAD QQYECVAEIG EGAYGKVFKA RDLKNGGRFV ALKRVRVQTG EEGMPLSTIR
     EVAVLRHLET FEHPNVVRLF DVCTVSRTDR ETKLTLVFEH VDQDLTTYLD KVPEPGVPTE
     TIKDMMFQLL RGLDFLHSHR VVHRDLKPQN ILVTSSGQIK LADFGLARIY SFQMALTSVV
     VTLWYRAPEV LLQSSYATPV DLWSVGCIFA EMFRRKPLFR GSSDVDQLGK ILDVIGLPGE
     EDWPRDVALP RQAFHSKSAQ PIEKFVTDID ELGKDLLLKC LTFNPAKRIS AYSALSHPYF
     QDLERCKENL DSHLPPSQNT SELNTA
//
